Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Blanchette

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Primary Pacemaker Insertion: Gender Differences In Prior Er UtilizationD Roy, C M Blanchette
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cachexia in the Us Health Care SystemJ Noone, C M Blanchette, D Roy, et al.
Journal of Medical Economics|March 24, 2017
Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney diseaseL A Clark, S Whitmire, S Patton, et al.
Diabetes Research and Clinical Practice|January 21, 2014
Diabetes complications and adverse health outcomes after coronary revascularizationBola F Ekezue, S B Laditka, J N Laditka, et al.
International Journal of Clinical Practice|March 29, 2014
Experiences and treatment patterns of hypogonadal men in a U.S. health systemE F Shortridge, P Polzer, P Donga, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Primary Pacemaker Insertion: Gender Differences In Prior Er UtilizationD Roy, C M Blanchette
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cachexia in the Us Health Care SystemJ Noone, C M Blanchette, D Roy, et al.
Journal of Medical Economics|March 24, 2017
Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney diseaseL A Clark, S Whitmire, S Patton, et al.
Diabetes Research and Clinical Practice|January 21, 2014
Diabetes complications and adverse health outcomes after coronary revascularizationBola F Ekezue, S B Laditka, J N Laditka, et al.
International Journal of Clinical Practice|March 29, 2014
Experiences and treatment patterns of hypogonadal men in a U.S. health systemE F Shortridge, P Polzer, P Donga, et al.
Pageof 1